search
Back to results

Rationalisation of Polypharmacy by the Geriatric Consultation Team (RASP-GCT)

Primary Purpose

Iatrogenic Disease

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Medication review, based on but not limited to the RASP list
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Iatrogenic Disease focused on measuring frailty, geriatric, elderly, polypharmacy

Eligibility Criteria

75 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Admitted to a non-geriatric ward
  • 75 years or older
  • Dutch speaking
  • Consultation by the GCT

Exclusion Criteria:

  • End-of-life
  • No drugs on admission

Sites / Locations

  • University Hospitals Leuven

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

GCT

GCT-RASP

Arm Description

In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.

Medication review, based on but not limited to the RASP list

Outcomes

Primary Outcome Measures

Number of medication-related recommendations by the geriatric consultation team.

Secondary Outcome Measures

Number of potentially inappropriate drugs at discharge, as identified by the RASP list.
Number of drugs at discharge, relative to the drugs on admission.
Acceptance rate of the GCT interventions by the treating physician.

Full Information

First Posted
May 26, 2014
Last Updated
June 13, 2014
Sponsor
Universitaire Ziekenhuizen KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT02165618
Brief Title
Rationalisation of Polypharmacy by the Geriatric Consultation Team
Acronym
RASP-GCT
Official Title
Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments. (* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)
Detailed Description
Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iatrogenic Disease
Keywords
frailty, geriatric, elderly, polypharmacy

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GCT
Arm Type
No Intervention
Arm Description
In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
Arm Title
GCT-RASP
Arm Type
Active Comparator
Arm Description
Medication review, based on but not limited to the RASP list
Intervention Type
Other
Intervention Name(s)
Medication review, based on but not limited to the RASP list
Other Intervention Name(s)
RASP, RASP list, Systematic medication review
Intervention Description
Systematic approach: Medication reconciliation Applying the RASP list Expert review (not based on the RASP list) Multidisciplinary discussion
Primary Outcome Measure Information:
Title
Number of medication-related recommendations by the geriatric consultation team.
Time Frame
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
Secondary Outcome Measure Information:
Title
Number of potentially inappropriate drugs at discharge, as identified by the RASP list.
Time Frame
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
Title
Number of drugs at discharge, relative to the drugs on admission.
Time Frame
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
Title
Acceptance rate of the GCT interventions by the treating physician.
Time Frame
Up to 72 hours after the GCT had given its recommendations.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Admitted to a non-geriatric ward 75 years or older Dutch speaking Consultation by the GCT Exclusion Criteria: End-of-life No drugs on admission
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lorenz R Van der Linden, PharmD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Johan Flamaing, MD, PhD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jos Tournoy, MD, PhD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Leuven
City
Leuven
State/Province
Flemish Brabant
ZIP/Postal Code
3000
Country
Belgium

12. IPD Sharing Statement

Citations:
PubMed Identifier
29970005
Citation
Van der Linden L, Hias J, Dreessen L, Milisen K, Flamaing J, Spriet I, Tournoy J. Medication review versus usual care to improve drug therapies in older inpatients not admitted to geriatric wards: a quasi-experimental study (RASP-IGCT). BMC Geriatr. 2018 Jul 3;18(1):155. doi: 10.1186/s12877-018-0843-y.
Results Reference
derived

Learn more about this trial

Rationalisation of Polypharmacy by the Geriatric Consultation Team

We'll reach out to this number within 24 hrs